Market access update
Key areas of focus at ISPOR 2023 include:
ISPOR 2023 provides you with the ideal opportunity to learn how Avalere has combined its healthcare consulting expertise with Policy Analysis Inc. (PAI) and PRMA Consulting, as a single capability within parent group, Fishawack Health. These strong US and global connections bring truly integrated innovative data, technology-driven solutions, and experienced-based insights to today’s most complex healthcare challenges.
In an interview ahead of ISPOR 2023, senior colleagues keenly anticipated the value that our connected teams will offer delegates at the upcoming exhibition:
“We are excited to be attending ISPOR 2023. The global pressures on price and focus on value are as strong as ever. With the advent of the Inflation Reduction Act, EUnetHTA 21, and pricing reforms in Germany, France, and Japan, the industry is being challenged on all fronts to clearly demonstrate the value of the innovation they are developing.At Fishawack Health we have strategically built out first-class capabilities across policy, market access, and HEOR to offer you a truly joined up service offering that meets your needs. We look forward to meeting with you to explore how we can partner with you to address the evolving landscape.”
“We understand policy, we understand market access, we understand evidence and value engagement – not only in the US, but also across Europe and the Asia-Pacific region. It’s not necessarily difficult to find expertise in any one of those areas, but it’s hard to find a company that delivers it all. I’m excited to introduce you to our integrated global offering at ISPOR 2023.”
“Avalere, PAI, and PRMA Consulting have come together as a single unified capability within Fishawack Health, connecting our fully integrated services and solutions with one goal in mind – solving clients’ problems the way that problem-solving should be done. This is changing the game for us, and it will be a game-changer for our clients as we continue to move ahead together.”
“ISPOR 2023 is a great place to meet our policy, access, value, and evidence experts. With deep knowledge of quickly evolving policy and market access landscapes, and the implications for portfolio and commercialization strategies, they will help you develop robust strategies and agile solutions for changing markets.” Jon Koch, CEO, Fishawack Health
ISPOR invites health policy makers, regulators, researchers, payers, and patients from across the world to Boston, to discuss the biggest issues affecting healthcare right now. With growing interest in the Inflation Reduction Act (IRA), it has never been a better time to set up a meeting with our team. The IRA will not just affect the pharmaceutical market in the US but have major ramifications around the world.
“This is a pivotal moment,” says Sarah Alwardt, Senior Vice President, Avalere Health. “It’s still not completely clear how the IRA is going to be implemented or how it will change over time, but if you’re looking for an expert consultancy to help you navigate that ambiguity, we are the right company with the right connections to help you do that.”
In addition to meeting our experts at booth #831, join Michael Ciarametaro, Principal, Avalere Health in a discussion, “The Day After Tomorrow: Evidence, Value, and Market Access After the IRA” on Tuesday May 9, 11:45 am – 12:15 pm, in the Exhibition Hall Theatre.
During this session, Michael and panelists, including Kim Caldwell, best known for leading the development and implementation of Medicare Part D at CMS and Sarah Alwardt, former Ontada and Humana analytics leadership, will be leveraging their public and private payer, HTA, evidence, and policy experience to debate these key issues:
If you are not attending ISPOR 2023, you don’t have to miss out: the expert team at Avalere Health is sharing weekly insights on Avalere.com.
Join Michael Ciarametaro, Principal, Avalere Health in a panel discussion, “Inflation Reduction Act (IRA) Negotiation: Closer to Government Price Setting or Traditional HTA?” on Tuesday May 9, 1:45 pm – 2:45 pm, in the Exhibition Hall Theater.
During this session, Michael and panelists Peter Neumann, a patient advocate, and Emily Freeman, a health services and outcomes researcher, will explore this question by examining key differences between price setting and traditional HTA, and their ramifications.
Another reason to meet members of our team at ISPOR 2023 is to discuss our new e-learning platform MALCOM (Market Access Learning Compendium).
“For the first time, we have captured the wealth of our market access expertise and are making it available as MALCOM e-learning. It’s a simple and consistent way to train your teams and keep them up to date on the HTA and pricing and reimbursement environment,” says Alison Lawrence, Director, PRMA Consulting.
“Expertise in policy, access, value and evidence is a fundamental part of achieving reimbursement and access to treatments,” she says. “MALCOM takes the pressure out of internal training by providing our knowledge in a flexible, on-demand e-learning application.”
Unlock and optimize product value from early development through to successful country submissions with our suite of unique digital applications:
 | Advanced HEOR modeling simplified |
 | Maximize the value of your asset portfolio at all stages of development |
 | Efficiently and effectively deliver high-quality multiple HTA and other payer submissions |
 | Track the evolving HTA and P&R landscape for key competitors or products of interest |
Quality Measures Navigator® Integrate quality measures into drug development and product launch planning
Federal Policy 360® Monitor, influence, or adapt to federal health policy activity, news, and trends affecting the US healthcare market
State Policy 360® Understand, influence, or adapt to health policy activity across all 50 states plus Washington, DC
Global Policy 360™ Understand how global developments in drug pricing and value, value-based purchasing and innovative contracting approaches, and novel therapies influence US markets
Cell & Gene Policy 360™ Keep informed of changes to the policy and market landscape as you prepare to launch a cell or gene therapy
Policy Edge™ Stay ahead with data-driven and actionable insights into Congressional and administrative policymakers’ priorities
Fishawack Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our 1,500+ experts combine their knowledge and expertise across our core disciplines – Medical; Marketing; Policy, Access, Value, and Evidence; and Consulting – to create the connections that make better health happen.
We partner with our clients to navigate the complex and rapidly changing healthcare ecosystem. Together, we realize the potential of strategies and solutions, to bring innovation to the hands of those who can benefit from it.
Meet with us at ISPOR US
The data you submit here will be processed by us, and our partners within Fishawack Health, as outlined in our privacy policy, cookie policy, and terms and conditions.
